<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269278</url>
  </required_header>
  <id_info>
    <org_study_id>B-2002/595-301</org_study_id>
    <nct_id>NCT04269278</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Blood Coagulation</brief_title>
  <official_title>The Effect of Dexmedetomidine on Blood Coagulation: In Vitro, Volunteer Study Using Rotational Thromboelastometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine may alter whole blood coagulation. However, little is known about the
      dose-response relationships according to the blood concentration of dexmedetomidine. The
      investigators have therefore performed the present study to measure the effect of
      dexmedetomidine on the coagulation pathway according to the drug concentration level using a
      rotational thromboelastometry test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FIBTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Intrinsic pathway values of rotational thromboelastometry analysis/ INTEM is not an acronym.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Extrinsic pathway values of rotational thromboelastometry analysis/ EXTEM is not an acronym.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>0 ng/ml</arm_group_label>
    <description>Blood specimen which was added 0 ul of dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 ng/ml</arm_group_label>
    <description>Blood specimen which was added 0.25 ul of dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 ng/ml</arm_group_label>
    <description>Blood specimen which was added 0.5 ul of dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 ng/ml</arm_group_label>
    <description>Blood specimen which was added 0.75 ul of dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 ul of dexmedetomidine</intervention_name>
    <description>Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine</description>
    <arm_group_label>0 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25 ul of dexmedetomidine</intervention_name>
    <description>Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine</description>
    <arm_group_label>0.5 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 ul of dexmedetomidine</intervention_name>
    <description>Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine</description>
    <arm_group_label>1.0 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.75 ul of dexmedetomidine</intervention_name>
    <description>Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine</description>
    <arm_group_label>1.5 ng/ml</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age: 20 to 65 years

          -  Body weight &gt; 50 kg

          -  Volunteers who provided informed consent

        Exclusion Criteria:

          -  Hematologic disease

          -  Anticoagulant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Seok Na, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Seok Na, MD., PhD.</last_name>
    <phone>+82-31-787-7507</phone>
    <email>hsknana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoseok Na, pf</last_name>
      <phone>82-31-787-7507</phone>
      <email>hsknana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyoseok Na, pf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

